A decade’s worth of engineering-infused biology
-
- The Scientist »
- Magazine »
- Features »
Features
Most Recent
Learn about the field’s first genetic circuits and read forecasts by George M. Church and J. Craig Venter of a future where man-made organisms pump out novel fuels, drugs, and therapies.
Researchers and pharma companies have tried to attack this disease by reducing amyloid plaques, but inflammation may be the real culprit.
Gut bacteria may be the missing piece that explains the connection between diet and cancer risk.
Successful vaccines have been created to protect against pathogenic bacteria and viruses. Why aren’t there any for combating fungal infections?
It may be time to reconsider an AIDS vaccine which is more human than viral, triggering the immune system in a way that no other vaccine does.
A new breed of vaccines aims to wean users off cocaine.
Can tumors—which can originate from, and often resemble, chronically inflamed tissue—be curtailed using familiar anti-inflammatory agents, without their side effects?
The study of how covalent marks on DNA and histones are involved in the origin and spread of cancer cells is also leading to new therapeutic strategies.
Subjects
- cancer
- cell & molecular biology
- clinical trials
- disease/medicine
- drug development
- funding
- genetics & genomics
- immunology
- microbiology
- neuroscience
Sub Categories
- Bio Business
- Capsule Reviews
- Careers
- Contributors
- Critic At Large
- Editorial
- Features
- Foundations
- Lab Tools
- Modus Operandi
- Notebook
- Profile
- Reading Frames
- Scientist to Watch
- Speaking of Science
- The Literature
- Thought Experiment
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
